Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Queensland Health
Merck
Harvard Business School
QuintilesIMS
Johnson and Johnson

Generated: July 19, 2019

DrugPatentWatch Database Preview

Patent: 6,939,376

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,939,376
Title: Drug-delivery endovascular stent and method for treating restenosis
Abstract:An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of a monocyclic triene immunosuppressive compound having an alkyl group substituent at carbon position 40 in the compound. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40-90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1-5 microns.
Inventor(s): Shulze; John E. (Rancho Santa Margarita, CA), Betts; Ronald E. (La Jolla, CA), Savage; Douglas R. (Del Mar, CA)
Assignee: Sun Biomedical, Ltd. (Hamilton Hm Ex, BM)
Application Number:10/133,814
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,939,376
Patent Claims:see list of patent claims

Details for Patent 6,939,376

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22 ➤ Sign Up Sun Biomedical, Ltd. (Hamilton Hm Ex, BM) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 6,939,376

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Express Scripts
Fuji
Daiichi Sankyo
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.